BACKGROUND:Fatigue is common among glioma patients undergoingradiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT. METHODS:Eligibility criteria included age≥18 years, Karnofsky performance status ≥60, and grade 2-4 glioma undergoing RT to a total dose of 50-60 Gy. Patients were randomized 1:1 to armodafinil or placebo for 8 weeks beginning within 10 days of starting RT. Fatigue and QOL were assessed at baseline, day 22, day 43, and day 56 with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), the Functional Assessment of Cancer Therapy - General (FACT-G), the Brief Fatigue Inventory (BFI), and the Cancer Fatigue Scale (CFS). The primary aim was to detect a difference in the 42-day change in FACIT-F fatigue subscale between the 2 groups using a 2-sample Wilcoxon statistic. RESULTS: We enrolled 81 patients total (42armodafinil and 39 placebo). Armodafinil did not significantly improve fatigue or QOL based on the 42-day change in FACIT-F fatigue subscale, FACT-G, CFS, or BFI. Further analysis suggests no difference between the arms even after accounting for the potential bias of missing data. Treatment was well tolerated with few grade 3 or 4 toxicities. CONCLUSIONS: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study. Further studies are needed to determine whether pharmacologic treatment improves fatigue in glioma patients undergoing RT.
RCT Entities:
BACKGROUND:Fatigue is common among gliomapatients undergoing radiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in gliomapatients undergoing RT. METHODS: Eligibility criteria included age ≥18 years, Karnofsky performance status ≥60, and grade 2-4 glioma undergoing RT to a total dose of 50-60 Gy. Patients were randomized 1:1 to armodafinil or placebo for 8 weeks beginning within 10 days of starting RT. Fatigue and QOL were assessed at baseline, day 22, day 43, and day 56 with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), the Functional Assessment of Cancer Therapy - General (FACT-G), the Brief Fatigue Inventory (BFI), and the Cancer Fatigue Scale (CFS). The primary aim was to detect a difference in the 42-day change in FACIT-F fatigue subscale between the 2 groups using a 2-sample Wilcoxon statistic. RESULTS: We enrolled 81 patients total (42 armodafinil and 39 placebo). Armodafinil did not significantly improve fatigue or QOL based on the 42-day change in FACIT-F fatigue subscale, FACT-G, CFS, or BFI. Further analysis suggests no difference between the arms even after accounting for the potential bias of missing data. Treatment was well tolerated with few grade 3 or 4 toxicities. CONCLUSIONS: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in gliomapatients undergoing RT in this pilot study. Further studies are needed to determine whether pharmacologic treatment improves fatigue in gliomapatients undergoing RT.
Authors: Brandi R Page; Edward G Shaw; Lingyi Lu; David Bryant; David Grisell; Glenn J Lesser; Drew C Monitto; Michelle J Naughton; Stephen R Rapp; Steven R Savona; Sunjay Shah; Doug Case; Michael D Chan Journal: Neuro Oncol Date: 2015-05-12 Impact factor: 12.300
Authors: T Okuyama; T Akechi; A Kugaya; H Okamura; Y Shima; M Maruguchi; T Hosaka; Y Uchitomi Journal: J Pain Symptom Manage Date: 2000-01 Impact factor: 3.612
Authors: David Schiff; Eudocia Q Lee; Lakshmi Nayak; Andrew D Norden; David A Reardon; Patrick Y Wen Journal: Neuro Oncol Date: 2014-10-30 Impact factor: 12.300
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Florien W Boele; Linda Douw; Marjolein de Groot; Hinke F van Thuijl; Wilmy Cleijne; Jan J Heimans; Martin J B Taphoorn; Jaap C Reijneveld; Martin Klein Journal: Neuro Oncol Date: 2013-08-07 Impact factor: 12.300
Authors: Anna Spathis; Kate Fife; Fiona Blackhall; Susan Dutton; Ronja Bahadori; Rose Wharton; Mary O'Brien; Patrick Stone; Tim Benepal; Nick Bates; Bee Wee Journal: J Clin Oncol Date: 2014-04-28 Impact factor: 44.544
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Anita R Peoples; Sheila N Garland; Michael L Perlis; Josée Savard; Charles E Heckler; Charles S Kamen; Julie L Ryan; Karen M Mustian; Michelle C Janelsins; Luke J Peppone; Gary R Morrow; Joseph A Roscoe Journal: J Cancer Surviv Date: 2017-01-19 Impact factor: 4.442
Authors: Katherine B Peters; Mary L Affronti; Sarah Woodring; Eric Lipp; Patrick Healy; James E Herndon; Elizabeth S Miller; Maria W Freeman; Dina M Randazzo; Annick Desjardins; Henry S Friedman Journal: Support Care Cancer Date: 2022-01-10 Impact factor: 3.603
Authors: Julia Day; Shlomit Yust-Katz; David Cachia; Jeffrey Wefel; Ivo W Tremont Lukats; Helen Bulbeck; Alasdair G Rooney Journal: Cochrane Database Syst Rev Date: 2022-09-12
Authors: D Tomlinson; P D Robinson; S Oberoi; D Cataudella; N Culos-Reed; H Davis; N Duong; F Gibson; M Götte; P Hinds; S L Nijhof; P van der Torre; S Cabral; L L Dupuis; L Sung Journal: Curr Oncol Date: 2018-04-30 Impact factor: 3.677
Authors: Julia Day; Shlomit Yust-Katz; David Cachia; Jeffrey Wefel; Lior H Katz; Ivo Tremont; Helen Bulbeck; Terri Armstrong; Alasdair G Rooney Journal: Cochrane Database Syst Rev Date: 2016-04-13